<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04665583</url>
  </required_header>
  <id_info>
    <org_study_id>020-101</org_study_id>
    <nct_id>NCT04665583</nct_id>
  </id_info>
  <brief_title>Prehab Prior to Undergoing Tricuspid Intervention</brief_title>
  <official_title>Single-Center, Prospective, Open-Label Study Standardizing a Prehabilitation Protocol to Optimize Patients Prior to Undergoing Tricuspid Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baylor Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will aim to standardize the prehabilitation protocol to optimize patients and&#xD;
      document the clinical and echo variables that could improve clinical outcomes of tricuspid&#xD;
      valve intervention.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prior to screening activities, each subject will be given an opportunity to ask questions and&#xD;
      to understand the details of study participation. Subjects who meet the inclusion and&#xD;
      exclusion criteria and have signed an informed consent form will be considered enrolled into&#xD;
      the study. After a subject is consented and enrolled in the study, data will be collected&#xD;
      prior to any intervention or surgery at the following time points: a) Screening/Baseline b)&#xD;
      Day 1 of Prehab c) Day 2 of Prehab d) Day 3 of Prehab e) Day 4 of Prehab, f) and any data&#xD;
      collected immediately prior to an intervention or incision (in the case of a surgical&#xD;
      patient)&#xD;
&#xD;
      Subjects meeting eligibility criteria with planned tricuspid intervention will receive&#xD;
      in-hospital optimization with THHBP's Prehab Protocol.&#xD;
&#xD;
      Prehabilitation will consist of careful pre-intervention assessment and personalized&#xD;
      optimization, guided by Investigator judgment, with a specific focus on right ventricular&#xD;
      function. This will be done by using a detailed echo acquisition protocol (Appendix 1).&#xD;
      Assessments will be collected according to the schedule of events below (Table 1.). Therapy&#xD;
      will include intravenous milrinone therapy and aggressive diuresis with evaluation for&#xD;
      clinical and functional signs of improvement, according to standard of care. If there are&#xD;
      clinical and functional signs of improvement before Day 4, and the subject is ready for TV&#xD;
      surgery or any other intervention, they will have Day 4 procedures performed. After the tests&#xD;
      and evaluations are completed, the Principal Investigator or Sub-Investigators will decide if&#xD;
      the patient is a candidate for TV surgery or another intervention&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 25, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in volume status according to daily input/outputs</measure>
    <time_frame>4-5 days (Day 1 to Day 4 of Prehab or day of surgical intervention)</time_frame>
    <description>daily input/outputs (mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in volume status according to weight</measure>
    <time_frame>5-6 days (Baseline to Day 4 of Prehab or day of surgical intervention)</time_frame>
    <description>daily weights (kg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Severity of Tricuspid Regurgitation by Echocardiographic assessment</measure>
    <time_frame>5 days (Baseline to Day 4 of Prehab)</time_frame>
    <description>severity of tricuspid regurgitation (mild, moderate, severe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Nutritional Status</measure>
    <time_frame>4 days (Baseline to Day 3 of Prehab)</time_frame>
    <description>Pre-albumin (mg/dL)</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Tricuspid Valve Disease</condition>
  <condition>Tricuspid Regurgitation</condition>
  <arm_group>
    <arm_group_label>Prehabilitation</arm_group_label>
    <description>All study patients will receive preoperative optimization with a standardized prehabilitation protocol prior to any intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Prehabilitation</intervention_name>
    <description>Prehabilitation will consist of careful pre-intervention assessment and personalized optimization, guided by Investigator judgment, with a specific focus on right ventricular function. This will be done by using a detailed echo acquisition protocol (Appendix 1). Assessments will be collected according to the schedule of events below (Table 1.). Therapy will include intravenous milrinone therapy and aggressive diuresis with evaluation for clinical and functional signs of improvement, according to standard of care.</description>
    <arm_group_label>Prehabilitation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        40 adult male or female patients undergoing tricuspid valve intervention at The Heart&#xD;
        Hospital Baylor Plano&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. â‰¥ 18 years of age&#xD;
&#xD;
          2. Moderate-Severe or Severe TR&#xD;
&#xD;
          3. Undergoing tricuspid valve surgical or catheter-based intervention&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Clinical instability according to the judgement of the Investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sarah M Hale, BA</last_name>
    <phone>4698144845</phone>
    <email>sarah.hale@bswhealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Preethi Ravindranathan, MS</last_name>
    <phone>469-814-4721</phone>
    <email>Preethi.Ravindranathan@BSWHealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Heart Hospital - Plano</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah M Hale, BA</last_name>
      <phone>469-814-4720</phone>
      <email>sarah.hale@bswhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Preethi Ravindranathan, MS</last_name>
      <phone>469-814-4845</phone>
      <email>Preethi.Ravindranathan@BSWHealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Timothy George, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Zack CJ, Fender EA, Chandrashekar P, Reddy YNV, Bennett CE, Stulak JM, Miller VM, Nishimura RA. National Trends and Outcomes in Isolated Tricuspid Valve Surgery. J Am Coll Cardiol. 2017 Dec 19;70(24):2953-2960. doi: 10.1016/j.jacc.2017.10.039.</citation>
    <PMID>29241483</PMID>
  </reference>
  <reference>
    <citation>Hamandi M, Smith RL, Ryan WH, Grayburn PA, Vasudevan A, George TJ, DiMaio JM, Hutcheson KA, Brinkman W, Szerlip M, Moore DO, Mack MJ. Outcomes of Isolated Tricuspid Valve Surgery Have Improved in the Modern Era. Ann Thorac Surg. 2019 Jul;108(1):11-15. doi: 10.1016/j.athoracsur.2019.03.004. Epub 2019 Apr 2.</citation>
    <PMID>30951698</PMID>
  </reference>
  <reference>
    <citation>Hamandi M, George TJ, Smith RL, Mack MJ. Current outcomes of tricuspid valve surgery. Prog Cardiovasc Dis. 2019 Nov - Dec;62(6):463-466. doi: 10.1016/j.pcad.2019.11.014. Epub 2019 Dec 2. Review.</citation>
    <PMID>31805294</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 23, 2020</study_first_submitted>
  <study_first_submitted_qc>December 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We do not have a plan to shared IPD to researchers outside of our research team. We will make available aggregate data and results in the form of publications. Internal BSWH monitors will have access to IPD.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

